Donaldson Company heads into its June earnings window with short sellers adding positions at the fastest pace in months and insiders heading for the exit.
Short interest has been the defining feature of this week's setup. Estimated shares short climbed 36% over the past month to 2.4% of the free float, with the move accelerating this week — up another 11% over the past seven days alone. The most recent reading of 2.83 million shares short is the highest level in the 30-day window ORTEX tracks. That said, 2.4% of float is not a structurally dangerous number, and the lending market stays loose: cost to borrow has been stable and unremarkable around 0.42%, while availability remains ample at close to 96%. The building short book looks less like a squeeze setup and more like a considered directional bet.
Options traders are not amplifying that caution. The put/call ratio of 0.63 sits marginally below its 20-day average of 0.64, with a z-score of just -0.38 — firmly within normal range. Call positioning is modestly ahead of puts, and neither extreme of the 52-week band (1.88 high, 0.04 low) is under any pressure. For all the short-side building, the options market is not flashing alarm.
The Street remains divided, and recent analyst moves have mostly gone in one direction: lower targets. Baird cut its price target to $95 (from $104) in late March while holding its Outperform rating — the firm's second target reduction in three months after a cut to $104 from $110 in February. Morgan Stanley trimmed to $91 from $93 in early March, maintaining Equal-Weight. Both moves followed Donaldson's February earnings print, when the stock fell 11% in a single session and extended that decline to 12% over the following five days. Against that backdrop, the consensus mean price target of $96.40 — versus the current price of $87.00 — implies roughly 10% upside, but targets have been migrating lower rather than higher since early calendar year 2026. Jefferies, which upgraded to Buy at $120 in January, looks like an outlier.
The insider picture reinforces caution. Director James Owens sold just under 20,000 shares across three days in mid-April at prices around $89, collecting roughly $1.75 million. Division president Guillermo Briseno sold a combined 20,600 shares in late March for just over $1.75 million. Net selling over the 90-day window reached approximately $3.5 million. All transactions carry low significance scores — these are not panic moves or 10b5-1 unwinds from C-suite executives — but the consistent direction, with no offsetting purchases, adds to the subdued tone.
The setup going into the June 3 earnings call is therefore shaped by three converging signals: a rising short book, targets drifting lower, and insiders cashing out. The February event provides the clearest anchor — an 11% single-day drop after a disappointing print. The bull case rests on Life Sciences segment strength and margin expansion; the bear case points to softness in aerospace and defense revenue alongside pressure in the cyclical mobile end markets. With the stock up 0.75% on the week and still 1.3% higher year-to-date, the market has not pre-assigned either outcome. The June print becomes the test of whether the short builders or the remaining bulls are reading Donaldson's industrial cycle correctly.
See the live data behind this article on ORTEX.
Open DCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
